Eisai's Newly Acquired Lorcaserin Faced With Regulatory Hurdle After Qnexa Advisory Committee Vote
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Weeks after securing U.S. rights for the first of three much-touted obesity drugs, Eisai and partner Arena now face an unsure future for lorcaserin after a U.S. FDA advisory committee voted against recommending approval for Vivus' Qnexa based on safety concerns